Pharmaceutical companies often face a strategic paradox: as research and development pipelines mature, internal assets can unintentionally compete for the same patient populations. Effective portfolio co-positioning requires early intervention, clear internal governance, and a departure from individual brand-centric mindsets to ensure commercial success and patient clarity. Industry leaders Jakub Kaczor and Peter Smith, both of Lumanity, emphasize that shifting from siloed brand management to a unified portfolio strategy is essential for navigating modern competitive landscapes.
In the pharmaceutical sector, the drive for innovation often leads firms to develop multiple therapies within a single disease area. While this R&D focus supports long-term growth, it frequently creates “internal rivalry,” where a company’s own products vie for market share, clinical trial participants, or healthcare provider attention. According to Lumanity’s strategy consulting framework, firms that fail to address these overlaps early risk diluting their overall market impact and confusing the very customers they intend to serve.
Addressing the Paradox of Internal Competition
Internal competition often stems from a decentralized approach where individual brand teams operate with significant autonomy. When each team prioritizes its specific product’s performance metrics, the broader portfolio’s commercial potential can suffer. Kaczor and Smith suggest that the primary challenge is overcoming “brand egos,” where the success of a single asset is prioritized over the collective health of the company’s portfolio. This misalignment can lead to fragmented messaging, redundant resource allocation, and a failure to capture the full value of the company’s R&D investments.
To mitigate these risks, organizations are increasingly turning to structured co-positioning processes. This involves mapping the future competitive landscape—not just against external rivals, but against the company’s own incoming pipeline. By defining the unique clinical or commercial niche for each asset well before launch, firms can create a cohesive narrative that guides healthcare providers and patients toward the most appropriate treatment option within the portfolio.
Structuring for Portfolio Success
Effective co-positioning is rarely achieved without strong, centralized oversight. Establishing a dedicated portfolio owner—a role responsible for the lifecycle of multiple products rather than a single brand—is a common strategy among leading life sciences firms to ensure accountability and strategic alignment. This governance structure allows for objective decision-making, particularly when resources must be reallocated to support the most promising assets or to pivot in response to changing market conditions.
The collaborative mindset required for this shift involves breaking down departmental silos. Sales, marketing, and medical affairs teams must be integrated into a unified strategy that views the portfolio as an ecosystem. This approach requires:
- Market-Grounded Planning: Utilizing real-world evidence and patient insights to differentiate assets based on clinical utility rather than internal convenience.
- Early Engagement: Starting the co-positioning dialogue during the Phase II or early Phase III development stages to prevent divergent brand identities from taking root.
- Customer-Centric Messaging: Ensuring that the value proposition for each product is distinct, clear, and easy for clinicians to distinguish, thereby reducing confusion in the prescribing process.
Designing for the Future
Market dynamics in the pharmaceutical industry are fluid. Regulatory shifts, the emergence of new therapeutic modalities, and changes in health technology assessment (HTA) requirements mean that a positioning strategy designed today may be obsolete in three years. Consequently, portfolio management must be an iterative process. Companies that successfully navigate this complexity are those that design their strategies to anticipate future competitive shifts rather than reacting to them after they occur.
For teams looking to refine their commercialization strategies, Lumanity offers ongoing insights through their commercialization podcast series, which covers the evolving tactical requirements of modern pharma strategy. Engaging with these resources can provide teams with the frameworks needed to foster better internal collaboration and improve the overall impact of their therapeutic portfolios.
Next Steps for Strategy Development
The next phase for firms looking to optimize their portfolio positioning involves an audit of current R&D pipelines against existing commercial assets. Companies should focus on identifying potential points of friction where internal products overlap and establishing a clear governance model to resolve these conflicts. For further analysis on these topics, professionals are encouraged to follow Jakub Kaczor and Peter Smith on LinkedIn for updates on the latest trends in strategy consulting and pharmaceutical commercialization.
Have you encountered instances where internal portfolio competition hindered a product’s success? Share your thoughts on how cross-functional collaboration can resolve these challenges below.